We're working on profiling this company soon. Let us know you're interested by sending us a request here »
We're working hard to bring you this company's profile. Register here to get an alert as soon we're done.
In the meantime, if you are interested in participating in placements on this stock click "Follow" on the toolbar above.
What’s in a name? Not much, according to the CEO of the now cashed-up Percheron, Dr James Garner. Fo...
Read ArticleArgent Biopharma packs its bags for London on a one-way ticket Patrys shares slump 50% on cancellat...
Read ArticleXi and Biden set to agree on restricting fentanyl Fentanyl is a synthetic opioid responsible for t...
Read ArticleThe ASX has ended the week lower, down 0.55pc on Friday Healthcare Sector remains defiant Small ca...
Read ArticleThe ASX has closed higher Healthcare leads sector gains Small caps led by KTA and FG1 The Aussi...
Read ArticleASX200 closes +0.28% higher Healthcare leads gains, ASX All Gold rises over +3% Small caps led by t...
Read ArticleGood morning, and welcome to Stockhead’s Top 10 at shortly-before-11-ish, to highlight the best (and...
Read ArticleThe S&P ASX 200 fell -3.8% in October with mid-caps falling -6.94% and small-caps down -5.45% f...
Read ArticleNews relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD f...
Read ArticleMomentum trading involves taking advantage of, and making profits from, upward trends in a stock. Th...
Read ArticleThe Week That Was The world looks very different this week after the addition of what Barclays econo...
Read ArticleASX futures were down 0.82 per cent heading into 8.30 am AEDT. The market is set for a day in th...
Read ArticleASX 200 closes higher for a fifth straight day All 11 Sectors make it home for supper Small caps l...
Read ArticleKazia to de-list from ASX and maintain its NASDAQ listing IMEXHS wins $2m contract with Colombia’s...
Read ArticleStockhead’s Top 10 at shortly-before-11-ish, produced as on-time as humanly possible, despite being...
Read ArticleBenchmark index finishes Friday ahead +0.4% Sectors led by Financials Small caps dominated by Di...
Read ArticlePIQ came out of trading suspension and surged 13pc PIQ says the US has set a national reimbursement...
Read ArticleFutures indicate the ASX will open positively this morning, buoyed by tech gains in the US and the e...
Read ArticleL’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supr...
Read ArticleAccording to the World Health Organisation (WHO), cancer is the leading cause of death globally. WHO...
Read ArticleThe FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergenc...
Read ArticleEarnings reports dominated headlines in August Despite solid results from ASX healthcare giants, th...
Read ArticleAustralian biotech has attracted US investments in the last five years Among ASX stocks to get fund...
Read ArticleBiotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two g...
Read ArticleThe end of pandemic and higher rates have subdued biotech market But there are signs now the sector...
Read ArticleThe ASX 200 had a positive finish to the day on the whole, on the back of the rates pause from the...
Read ArticleStockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) pe...
Read ArticleKazia Therapeutics (ASX:KZA) has announced that its lead program, paxalisib, has been awarde...
Read ArticleAvita Medical receives US FDA premarket approval for its RECELL System to treat vitiligo Telix will...
Read ArticleBiotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We...
Read ArticleKazia Therapeutics (ASX:KZA) recently attended and participated in the Cancer Moonshot Brain...
Read ArticleOrphan diseases are those impacting less than 200,000 patients Orphan drug designation ensures an e...
Read ArticleLittle Green Pharma gets extended contract from the French government US FDA’s decision paves the w...
Read ArticleThe ASX 200 opened half a per cent higher this morning, with 9 of 11 sectors positive in intraday tr...
Read ArticleKazia Therapeutics (KZA) promotes its Chief Medical Officer, John Friend, to the role of CEO followi...
Read ArticleThe ASX is expected to open higher on a new week after gains continued across New York on Friday nig...
Read ArticleArtificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discove...
Read ArticleStockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) pe...
Read ArticleThe ASX slid to close flat today, after realising we were in danger of making some money Materials...
Read ArticleThe FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have g...
Read ArticleThe S&P ASX 200 rose 7.64%, in its best start to a year ever as global markets rally In a stron...
Read ArticleShareCafeAus shares close 0.07% lower but rise 6.2% in January by Peter Milios Australian shares f...
Read ArticleShareCafeHigh cost of living causes a fall in retail sales: ASX up 0.22% at noon by Peter Milios R...
Read ArticleJapanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based devic...
Read ArticleASX 200 holds steady around +0.8% since lunch Australian Pacific Coal CEO David Conry has left the...
Read ArticleKazia Therapeutics (KZA) launches $4.5 million via a placement to drive its clinical program toward...
Read ArticleStockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) pe...
Read ArticleWhat a solid day it’s been for the ASX today, with the benchmark maintaining a strong run past +1.1%...
Read ArticleThe benchmark looks like it’s been working hard, but really not much has changed Turaco Gold hits s...
Read ArticleGlobal share markets rally continue to rally in November despite ongoing economic and geopolitical...
Read ArticleShareCafeASX opens to 7-month high after Powell’s positive news: Aus shares up 0.8% by Peter Milios...
Read ArticleKazia’s positive results published in a Journal Cochlear’s proposed acquisition raised concerns wit...
Read ArticleOncology-focused drug development company Kazia Therapeutics (ASX:KZA) has announced the pub...
Read ArticleASX health stocks have been out of favour this year with rotation away from growth to value sector...
Read ArticleSmall caps up 0.86% while global markets wait for US midterm election results Aussies have hit a...
Read ArticleStockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) pe...
Read ArticleIt’s quarterlies season again as the ASX market announcements page becomes increasingly flooded with...
Read ArticleShareCafeASX increases slightly ahead of today’s rate rise: Aus shares 0.3% higher at noon by Peter...
Read Article28 Oct 2022 - A snapshot of the stocks on the move featuring Kazia Therapeutics(ASX:KZA), Green Tec...
Read ArticleShareCafeUS tech earnings weighing down Aus tech sector: ASX falls 0.62% at noon by Lauren Hayes D...
Read ArticleShareCafeStocks of the Hour: KZA, GT1, WR1 Yesterday after close, Kazia The...
Read ArticleKazia Therapeutics’ (KZA) paxalisib brain cancer drug demonstrates positive efficacy signals against...
Read ArticleWe take a look at how the 15 biotech IPOs that listed in 2021 are faring now Only two IPO stocks fr...
Read ArticleBlood clot programs have taken the spotlight recently as new discoveries made Two ASX health stocks...
Read ArticleDual-listed brain cancer specialist Kazia Therapeutics is preparing for a possible launch of its dru...
Read ArticleASX 200 drops load circa 1430 (AEST) ends 0.4% lower Small caps index laughs openly in face of dan...
Read ArticleUnlike the majority of biotech players, Kazia Therapeutics has emphasised diversity in its clinical...
Read ArticleShareCafeEvening Report: 8 August, 2022 by Paul Sanger After falling early in the session, the ASX...
Read Article08 Aug 2022 - A snapshot of the stocks on the move featuring Kazia Therapeutics (ASX:KZA), Mesoblast...
Read ArticleShareCafeLunch Report: 8 August, 2022 by Paul Sanger On the ASX this week we kick off the earnings...
Read ArticleShareCafeStocks of the Hour: 8 August, 2022 Kazia Therapeutics Limited (ASX...
Read ArticleAcrux and Lumos are waiting for FDA’s approvals Paradigm will present Phase 2 results Neuren commen...
Read ArticleAn additional news report on the recommendation, valuation, forecast and opinion changes for ASX-lis...
Read ArticleKazia Therapeutics (KZA) presents “promising” new data from an ongoing phase I clinical trial of it...
Read ArticleOncology-focused drug developer Kazia Therapeutics (ASX: KZA) has presented promising new data from...
Read ArticleThe ASX 200 will open slightly lower on Monday US non-farm payrolls surprise on the upside, but Wal...
Read ArticleShareCafeThe Week that Was – August 1-5, 2022 We at ShareCafe understand you are busy and may not ha...
Read ArticleShareCafeLunch Report: 5 August, 2022 by Tim McGowen Gold stocks are stronger across the board as...
Read ArticleShareCafeGlobal Biotech Turnaround Looks to Be Underway Signs of life are emerging in the global bio...
Read ArticleShareCafeKazia: AGILE Hurdle Missed but Significant Value Remains Corporate Connect analyst Marc Sin...
Read ArticleThe ASX 200 is up 0.6%, the XEC small caps index is down 0.8% Tomorrow is RBA day, Wednesday is OP...
Read ArticleIn case you were wondering, it is the Kazia Therapeutics Ltd (ASX: KZA) share price that’s crashi...
Read ArticleStockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) per...
Read ArticleUS FDA approves the first clinical trial using naturally derived psychedelic drugs It could open po...
Read ArticleSYDNEY, July 12, 2022 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an onco...
Read ArticleKazia Therapeutics (ASX: KZA) has launched a new scientific advisory board (SAB) consisting of “worl...
Read ArticleShareCafeEvening Report: 6 July, 2022 by Melissa Darmawan Australia’s trade surplus hit a record h...
Read ArticleShareCafeLunch Report: 7 July, 2022 by Melissa Darmawan Australian stocks have rebounded, helped b...
Read Article07 Jul 2022 - A snapshot of the stocks on the move, featuring Elsight (ASX:ELS), Kazia Therapeutics...
Read ArticleKazia Therapeutics’ (ASX: KZA) lead drug candidate paxalisib has been awarded rare paediatric diseas...
Read ArticleA recent research reveals which biotech segments VCs are ploughing billions of dollars into We list...
Read ArticleSYDNEY, July 6, 2022 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncol...
Read ArticleOncology-focused drug developer Kazia Therapeutics (ASX: KZA) has made good progress in the first si...
Read ArticleKazia Therapeutics (ASX:KZA) has announced that the US FDA has granted Orphan Drug Designati...
Read ArticleSYDNEY, June 17, 2022 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an onco...
Read ArticleThe US FDA has awarded Kazia Therapeutics (KZA) Orphan Drug Designation (ODD) for its paxalisib dru...
Read ArticleHighlights Kazia Therapeutics’ lead drug candidate, Paxalisib, secures ODD from the FDA for the...
Read ArticleKazia gets designation approval from US FDA Lumos signs contract to make at-home screening test pro...
Read ArticleKazia Therapeutics (ASX: KZA) has collared orphan drug designation (ODD) from the United States Food...
Read ArticleShareCafeEvening Report: 14 June, 2022 by Paul Sanger The Australian sharemarket has suffered its...
Read Article“Positive data” is being presented regarding the activity of Kazia Therapeutics’ (ASX: KZA) lead dru...
Read Article14 Jun 2022 - A snapshot of the stocks on the move featuring Kazia Therapeutics (ASX:KZA), Westgold...
Read ArticleKazia Therapeutics (KZA) sees new data presented for its brain cancer drug, Paxalisib, highlighting...
Read ArticleSYDNEY, June 13, 2022 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an onco...
Read ArticleOncology-focused drug developer Kazia Therapeutics (ASX: KZA) is expanding a phase two study of its...
Read ArticleSYDNEY, June 7, 2022 Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused dru...
Read ArticleShareCafeQueuing at the ATM: ASX small caps discover a handy source of funding ASX-listed small cap...
Read ArticleSYDNEY, June 3, 2022 /PRNewswire/ – Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncol...
Read ArticleOncology-focused drug development company Kazia Therapeutics (ASX: KZA) has confirmed the multi-drug...
Read ArticleSYDNEY, May 31, 2022 /PRNewswire/ – Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncol...
Read ArticleSYDNEY, May 23, 2022 /PRNewswire/ – Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncol...
Read ArticleSYDNEY, May 17, 2022 /PRNewswire/ – Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), a late-s...
Read Article11 May 2022 - A snapshot of stocks in the healthcare sector, including Antisense Therapeutics (ASX:A...
Read ArticleThe deep sell down of the US biotech sector has resulted in the valuation of many of the ASX-listed...
Read ArticleThe Healthcare sector has been struggling as the pandemic wanes But most money managers are still b...
Read ArticleOncology-focused drug development company Kazia Therapeutics (KZA) establishes an “at-the-market” e...
Read ArticleOncology-focused biotechnology company Kazia Therapeutics (ASX: KZA) has established an ‘at-the-mark...
Read ArticleKazia Therapeutics (ASX:KZA) has established an ‘at-the-market’ equity program with Oppenhei...
Read ArticleKazia Therapeutics (ASX: KZA) is preparing to present the results of a phase II study evaluating its...
Read ArticleOncology-focused drug development company Kazia Therapeutics (ASX:KZA) has announced that it...
Read ArticleThe healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak mark...
Read ArticleSYDNEY, April 8, 2022 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an onco...
Read ArticleSYDNEY, April 8, 2022 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), a late...
Read ArticlePro Medicus signs $32m deal in the US Kazia shows promise with lead drug paxalisib in child cancer...
Read ArticleKazia Therapeutics (ASX: KZA) has revealed pre-clinical data that its drug paxalisib demonstrates ac...
Read ArticleShareCafeWebinar Recap – SLB, MX1, KZA & AKO Catch up on the full webinar with presentations fr...
Read ArticleShareCafeKazia Therapeutics (ASX: KZA) – Webinar presentation James Garner – CEO & MD – Kazia T...
Read ArticleBiotech sector has had a tough time recently But there are signs of things improving this year A lo...
Read ArticleShareCafeKey Points To Remember When Investing in Biotech Companies In my role as Research Analyst f...
Read ArticleSYDNEY, March 21, 2022 /PRNewswire/ – Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), a late...
Read ArticleTelehealth was already a growing space even before the pandemic, but COVID had launched it into the...
Read ArticleSYDNEY, Feb. 28, 2022 /PRNewswire/ – Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an onco...
Read ArticleThis important milestone kicks off an exciting year for Kazia, with at least six potential data read...
Read ArticleOncology-focused drug development company Kazia Therapeutics (ASX: KZA) has recruited its first pati...
Read ArticleGBM AGILE, the pivotal study of paxalisib in glioblastoma, is well-advanced, having commenced recrui...
Read ArticleKazia Therapeutics says it had $15.2 million in cash at the end of December 2021 having comm...
Read ArticleShareCafeBuying Opportunities Beckon Amid Biotech Bloodbath The sharp retreat in global biotech valu...
Read ArticleThe ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial t...
Read ArticleOncology-focused and clinical stage biotechnology company Kazia Therapeutics (ASX: KZA) has reported...
Read ArticleSYDNEY, Feb. 7, 2022 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncol...
Read ArticleSYDNEY, Jan. 25, 2022 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an onco...
Read ArticleSYDNEY, Jan. 7, 2022 /PRNewswire/ – Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncol...
Read ArticleAt the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, be...
Read ArticleIt’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and...
Read ArticleThe life sciences sector has emerged into the spotlight ever since the pandemic began. In the US, th...
Read ArticleSYDNEY, Dec. 14, 2021 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an onco...
Read ArticleKaren Krumeich "brings to Kazia more than 30 years of experience in corporate finance, focused almos...
Read Article“There are no changes to earnings in the forecast period and we maintain our Buy (Speculative) recom...
Read ArticleIt’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 los...
Read Article03 Dec 2021 - Kazia Therapeutics (ASX:KZA) has announced positive results from its Phase II study in...
Read ArticleKazia Therapeutics (KZA) opens the trading day green after reporting positive final results from a...
Read ArticleThe ASX 200 Health Index (XHJ) is down by 0.67% at the time of writing, compared to the broader inde...
Read ArticleThe study tested paxalisib's effectiveness in patients whose genetic profile confers resistance to t...
Read ArticleSYDNEY, Nov. 29, 2021 /PRNewswire/ – Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an onco...
Read ArticleThe Sydney-based company’s flagship drug, paxalisib, is a candidate in a multi-drug platform study d...
Read ArticleHe’s baaack! Fresh from founding and listing immune-oncology play Chimeric, Paul Hopper can add Radi...
Read ArticleIt’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 los...
Read ArticleHighlights As per experts, the global cancer drug market is likely to accelerate in the upcoming...
Read ArticleSYDNEY, Nov. 16, 2021 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an onco...
Read ArticleDr Friend will be responsible for overseeing the development and commercialization of Kazia’s pipeli...
Read ArticleSYDNEY, Nov. 11, 2021 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an onco...
Read ArticleThe ASX 200 Health Index (XHJ) is down by 1.0% at the time of writing, compared to the broader index...
Read Article"There remains a desperate need for new treatment options in this disease, and we hope that paxalisi...
Read ArticleWall Street falls as US inflation hits 30-year high US stocks continued their slide overnight, as th...
Read ArticleShareCafeDue Diligence Webinar – Kazia Therapeutics Presenter – James Garner CEO & Managing Dir...
Read ArticleKazia Therapeutics (KZA) enrols its first patient in the upcoming phase one clinical trial of EVT80...
Read ArticleThe oncology-focused drug development company licensed the investigational cancer therapy, known as...
Read ArticleThe ASX 200 Health Index (XHJ) is up by 0.40% at the time of writing, compared to the broader index...
Read ArticleASX-listed mobile health (mHealth) company Advanced Human Imaging (AHI) is moving forward with its...
Read ArticleThe Maxim Group has also put a 12-month target price of US$18 per ADS, saying the current stock pric...
Read ArticleEdison has increased its valuation to A$375 million or A$2.83 per basic share from A$346 million or...
Read ArticleSYDNEY, Oct. 6, 2021 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology...
Read ArticleSYDNEY, Sept. 11, 2021 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an onc...
Read ArticleShareCafeHidden Gems Webinar Recap – CYP, AT1, NSB & KZA Catch up on the full webinar with pre...
Read ArticleShareCafeA high quality pipeline of cancer drugs James Garner – Managing Director & CEO – Ka...
Read ArticleAlthough earnings results were the main theme in August, there were also some notable healthcare bre...
Read Article“The second calendar quarter has been a busy and productive period for Kazia, as we bed down three s...
Read ArticleKazia says its future success will be measured by commercialisation milestones after the company rec...
Read ArticleIt’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 7...
Read ArticleThe ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the...
Read ArticleAll upfront payments from outbound partnering transactions in the first quarter have been received b...
Read ArticleSYDNEY, July 21, 2021 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), a leading...
Read ArticleIt’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 7...
Read ArticleIt’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52...
Read ArticleThe fortunes of ASX healthcare shares can often swing on one momentous milestone. Examples of such...
Read ArticleSYDNEY, June 30, 2021 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an onco...
Read ArticleThe GBM AGILE pivotal study of paxalisib is recruiting ahead of expectations, with almost 25 sites n...
Read ArticleSummary Afterpay jumps on plans to expand reach with U.S. merchants Althea enters South African...
Read ArticleSummary The ASX 200 closed lower for the second day in a row, falling 0.32% to 7,275.30. The AS...
Read ArticleA Kazia-licensed oncology drug has secured manufacturing patents in two key countries, providing an...
Read ArticleOncology-focused drug development company Kazia Therapeutics (ASX:KZA) has announced the gra...
Read ArticleRecent advances in our still-shallow understanding of the human brain have led to a renewed interest...
Read ArticleSYDNEY, June 15, 2021 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an onco...
Read ArticleShares in Kazia Therapeutics Ltd (ASX: KZA) lifted today after news its investigational drug Paxali...
Read ArticleA new study will evaluate the efficacy of Kazia’s paxalisib candidate in patients with newly diagnos...
Read ArticleShareCafeAlzheimer’s Decision Sends Positive Message to Aussie Biotechs The US Food and Drug Adminis...
Read ArticleHere’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has ret...
Read ArticleSYDNEY, June 7, 2021 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncol...
Read ArticleThe Kazia Therapeutics Ltd (ASX: KZA) share price is edging lower, down 2% in morning trade. Below...
Read ArticleThe DFCI study (NCT04906096) is an open-label phase II clinical trial of paxalisib in PCNSL and is e...
Read ArticleDuring the March quarter, the oncology-focused drug development company saw maiden revenue of A$5.3...
Read ArticleIt was a good day for some of ASX-listed cancer therapy stocks yesterday, with three companies relea...
Read ArticleDuring the quarter, the oncology-focused drug development company saw maiden revenue of A$5.3 millio...
Read ArticleDuring the quarter, the oncology-focused drug development company saw maiden revenue of A$5.3 millio...
Read ArticleThe company gained exclusive global rights to the drug for €1 million (A$1.6 million) upfront, €308...
Read ArticleShareCafeThe Week that Was – April 19-23, 2021 We at ShareCafe understand you are busy and may not h...
Read ArticleKazia Therapeutics (ASX:KZA) has entered into a worldwide exclusive licensing agreement and...
Read ArticleKazia Therapeutics (ASX:KZA)‘s chief executive says he could do with catching up on sleep after a “w...
Read ArticleMuch of Kazia’s operational capacity has opened up with the inclusion of paxalisib in the GBM AGILE...
Read ArticleKazia expects to explore potential uses of EVT801 during the clinical program, including renal cell...
Read ArticleShareCafeKazia Licenses New Oncology Drug Candidate Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZ...
Read ArticleSYDNEY, April 19, 2021 /PRNewswire/ — Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an oncolo...
Read ArticleThe ASX finished the day higher but the all time high reached prior to COVID-19 still eludes it. The...
Read ArticleSmall caps have gained again – rising for the fourth day in a row and the 10th time out of 11 sessio...
Read ArticleCorporate Connect has increased the company’s share price target from A$2.25 to A$2.60 a share on th...
Read ArticleKazia Therapeutics has executed two licensing deals in the space of a month, proving the company is...
Read ArticleUranium explorer 92 Energy (ASX:92E) is among several companies lined up to list on the ASX this or...
Read ArticleSmall caps have gained for a sixth straight day, even as their larger peers declined. The Small Ordi...
Read ArticleThe Kazia Therapeutics Ltd (ASX: KZA) share price is backtracking today despite announcing encourag...
Read ArticleHealthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financia...
Read ArticleSource:Olena Yakobchuk, Shutterstock Summary Oncology-centric healthcare company Kazia Therapeu...
Read ArticleThe Kazia Therapeutics Ltd (ASX: KZA) share price is shooting for the moon today. The positive move...
Read ArticleSYDNEY, March 29, 2021 /PRNewswire/ — Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an onc...
Read ArticleToday the ASX was down a 0.3% and only materials (resources) and industrials were in positive territ...
Read ArticleHere’s our fortnightly wrap of all the news driving ASX health stocks. It’s been a mixed two weeks f...
Read ArticleEmerging Australia oncology-focused biotechnology company Kazia Therapeutics (ASX:KZA) has a...
Read ArticleSYDNEY, March 2, 2021 /PRNewswire/ — Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Aust...
Read ArticleShareCafeKazia Licenses Ovarian Cancer Drug to Swedish Pharmaceutical Company Australian oncology-f...
Read ArticleOasmia Pharmaceutical AB will assume worldwide exclusive rights to develop and commercialise Cantrix...
Read ArticleThe company’s cash balance for the December 2020 quarter is an increase from the A$8.7 million recor...
Read ArticleShareCafeHidden Gems Webinar Recap – Perennial value management, ADV, LKE, KZA Catch up on the full...
Read ArticleShareCafeKazia Therapeutics (ASX:KZA) – Hidden Gems Webinar Presentation Presenter – James Garner...
Read ArticleKazia and its collaborators are currently running six clinical studies of paxalisib across multiple...
Read ArticleKazia and its collaborators are currently running six clinical studies of paxalisib across multiple...
Read ArticleSummary Dual-listed oncology player Kazia Therapeutics commenced recruitment for the GBM AGILE p...
Read ArticlePositive data from GBM AGILE is expected to support the registration of paxalisib in the US and othe...
Read ArticleThe company is developing innovative, high-impact drugs for cancer and has one of the leading assets...
Read ArticleBell Potter has maintained its Speculative Buy rating and valuation of A$2.76 per share for Kazia wi...
Read ArticleBell Potter has maintained its Speculative Buy rating and valuation of A$2.76 per share for Kazia (c...
Read ArticleThe company's clinical trial of multiple therapies is set to open in the US in the first half of 202...
Read ArticleSource: Shutterstock Summary Kazia Therapeutics announced the execution of a Letter of Intent w...
Read ArticleThe clinical trial will initially open in the US in the first half of 2021, with expansion to other...
Read ArticleThe trial returned positive results and the company intends to shift towards partnering activity to...
Read Article09 Dec 2020 - Kazia Therapeutics (ASX:KZA) released data from their phase 1 study of Cantrixil in pa...
Read ArticleEdison Investment Research has increased its valuation on Kazia to A$2.04 per share from A$1.54 per...
Read ArticleThe Kazia Therapeutics Ltd (ASX: KZA) share price is one of the best performers on the ASX this pas...
Read ArticleThe Kazia Therapeutics Ltd [ASX:KZA] share price is following an upward trend. While this small-cap...
Read ArticleShareCafeWhy Kazia Therapeutics is Australia’s biotech shining star Kazia Therapeutics share price h...
Read ArticleSummary Kazia Therapeutics has announced that it will present the summary of paxalisib’s new Phas...
Read ArticleThe paxalisib Phase II study remains ongoing, with final data expected in the first half of 2021.
Read ArticleDuring the September quarter the company’s Paxalisib drug was granted special designations by US FDA...
Read ArticleThe company’s investigational new drug paxalisib is being developed to treat glioblastoma (GBM), an...
Read ArticleKazia is laying the groundwork to develop its investigational new drug paxalisib for glioblastoma an...
Read ArticleAustralian oncology-focused biotechnology company Kazia Therapeutics (ASX:KZA) has announced...
Read ArticleGBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment) is an international platfor...
Read ArticleProceeds form the entitlement offer will position Kazia as a late-stage global oncology company with...
Read ArticleBy Peter Switzer, Switzer Report Lots of smaller companies I like One thing I’ve personally learnt t...
Read ArticleShareCafeAntisense Eyes A ‘Golden Ticket’ In The US – And Early European Approval For Its Rare Child...
Read ArticleAustralian oncology-focused biotechnology company Kazia Therapeutics (ASX:KZA) has announced...
Read ArticleA number of companies got a nice share price boost after positive announcements this week Starpharma...
Read ArticleThe funding will position Kazia as a late-stage global oncology company with a highly-compelling ass...
Read ArticleThe financing will position Kazia as a late-stage global oncology company with a highly-compelling a...
Read ArticleThe Dana-Farber Cancer institute will initiate an open-label phase II clinical trial of paxalisib in...
Read ArticleSydney-based biotech outfit Kazia Therapeutics is hunting a $25.2 million cash injection, to fund it...
Read ArticleShareCafeKazia Therapeutic’s New Collaboration Gives Their Cancer Drug New Potential For Treatment O...
Read ArticleThe institute will initiate an open-label phase II clinical trial of paxalisib in primary central ne...
Read ArticleKazia said the collaboration will investigate the use of its investigational new drug, paxal...
Read ArticleEdison Investment Research has reinitiated coverage on Kazia with a valuation of A$145 million or A$...
Read ArticleHealthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financia...
Read ArticleThe company’s paxalisib treatment for malignant glioma has been recently granted Orphan Drug Designa...
Read ArticleShareCafeWith A ‘Ticket To Ride’, Kazia Wows Investors With Its Rare-Cancer Story As the politica...
Read ArticleThis status for potential treatments for rare diseases provides a period of 7.5 years data exclusivi...
Read ArticleA quick wrap of the ASX’s key winners and losers on Thursday, August 20. Data is taken after the mar...
Read ArticleKazia Therapeutics Ltd (ASX: KZA) share price has skyrocketed 34% today after announcing the US Foo...
Read ArticleJust under two weeks ago, Kazia Therapeutics Ltd [ASX:KZA] was making headlines. The company had rec...
Read ArticleAustralian oncology-focused biotechnology company Kazia Therapeutics (ASX: KZA) has been granted Fas...
Read ArticleCancer-fighting biotech Kazia Therapeutics (ASX:KZA) has received another approval from US health au...
Read ArticleFast Track Designation (FTD) is designed to expedite development of pharmaceutical products which de...
Read ArticleStockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade....
Read ArticleKazia Therapeutics (ASX:KZA), an Australian oncology-focused biotechnology company, has anno...
Read ArticleStockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade....
Read ArticleSummary Kazia Therapeutics’ paxalisib awarded Rare Pediatric Disease Designation by the US FDA....
Read ArticleThe share price of oncology-focused biotech firm, KAZIA Therapeutics Ltd [ASX:KZA], soared this morn...
Read ArticleA quick wrap of the ASX’s key winners and losers on Friday, August 7. Data is taken after the market...
Read ArticleThe Kazia Therapeutics Ltd (ASX: KZA) share price has today smashed its 52-week high on news that t...
Read ArticleThe US FDA has awarded RPDD to paxalisib for the treatment of Diffuse Intrinsic Pontine Glioma, a ra...
Read ArticleThe US FDA has awarded RPDD to paxalisib for the treatment of Diffuse Intrinsic Pontine Glioma, a ra...
Read ArticleStockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade....
Read ArticleKazia Therapeutics (ASX: KZA) has been awarded Rare Pediatric Disease Designation (RPDD) for its lea...
Read ArticleBell Financial Group (ASX:BFG) is expecting to book a higher $23.5m first-half profit, but investors...
Read ArticleShareCafeKazia Therapeutics – ShareCafe Hidden Gems Webinar Presentation Kazia Therapeutics CEO D...
Read ArticleShareCafeHidden Gems Webinar Recap – SPT, KZA, MEM, ANP We continue to unearth small-cap companie...
Read ArticleThe Cantrixil phase I study is now complete and analysis is underway, with final data expected in th...
Read ArticleThe biotech has delivered all milestones to date, with multiple data read-outs expected over 6-12 mo...
Read ArticleShareCafeUnderstanding Biotechs Starts With Understanding How Drugs Are Named? Drugs and biologics o...
Read ArticleThe company will present findings to date at the upcoming virtual American Society of Clinical Oncol...
Read ArticleThe proceeds will be applied directly to progressing and enriching the company’s research and develo...
Read ArticleParticipating in small cap raises is proving lucrative for investors, with shares in 47 small caps t...
Read ArticleThe proceeds will be applied directly to progressing and enriching the company’s research and develo...
Read ArticleKazia recently confirmed further positive data from its Phase I study of Cantrixil (TRX-E-001-2) in...
Read ArticlePre-revenue biotech and medtech companies are still not eligible for the Jobkeeper wage subsidy acco...
Read ArticleProceeds from the SPP and recent placement will be used to progress the paxalisib clinical trial pro...
Read ArticleThe company has received a large volume of acceptances in the last two days and wishes to ensure tha...
Read ArticleIt’s still a relatively difficult market to raise capital in, particularly at the junior end, but th...
Read ArticleClinical trials are being shuttered in increasing numbers in Australia because of the risks posed by...
Read ArticleThe COVID-19 pandemic has led to 527 clinical trials being shut down in Australia and New Zealand th...
Read ArticlePatients recruited to the study all had advanced metastatic ovarian cancer and had failed or become...
Read ArticlePhase II study data recently provided evidence that paxalisib may achieve meaningful extension of pa...
Read ArticleThe company will also launch a Share Purchase Plan to allow eligible existing holders to acquire new...
Read ArticleThe oncology-focused biotechnology company has two clinical-stage drug development candidates in the...
Read ArticleIn proof that biotechs will deliver market returns even during a pandemic, two companies this mornin...
Read ArticleKazia recently completed recruitment for the phase II clinical trial testing its development drug pa...
Read ArticleThe Australian oncology-focused biotechnology company has two clinical-stage drug development candid...
Read ArticleKazia is an oncology-focused biotechnology company developing the drug paxalisib to treat brain canc...
Read ArticleNeuren Pharmaceuticals (ASX: NEU) is getting interesting results from a mouse trial of a treatment f...
Read ArticlePeter Switzer speaks to Kazia Therepeutics (KZA) CEO James Garner about the company's work to develo...
Read ArticleKazia had a transformational year in 2019 with initial clinical efficacy read-outs from both its key...
Read ArticleKazia has concrete signals of clinical efficacy for its GDC-0084 program paxalisib in the exact pati...
Read ArticleKazia plans to participate in the GBM AGILE international study as its primary path-to-market strate...
Read ArticleYou may have heard the saying “it’s not brain surgery” in the context of trying to prove something e...
Read ArticleThe health sector was the most successful sector on the ASX in 2019. Various small caps made several...
Read ArticleThe company anticipates further data read-outs in calendar 2020, along with the transition of GDC-00...
Read ArticleKazia plans to participate in the GBM AGILE international multi-drug adaptive phase II / III study a...
Read ArticleKazia Therapeutics’ (ASX: KZA) lead drug GDC-0084 has been selected for use in GBM AGILE, which is a...
Read ArticleStockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade....
Read ArticleAustralian oncology company Kazia Therapeutics (ASX:KZA) has released interim data from its...
Read ArticleMajority of patients in the first stage of the study remain alive more than a year after diagnosis o...
Read ArticleBiotechnology company Kazia Therapeutics (ASX: KZA) has reported early data from a phase 2 study int...
Read ArticleThe company has capitalised on recent share price appreciation driven by emerging data from broad-ba...
Read ArticleGot 90 seconds? Then listen to Kazia Therapeutics CEO and Executive Director Dr. James Garner tell u...
Read ArticleThere are no shortage of small cap health and biotech companies listed on the ASX — around 140 or so...
Read ArticleDual Listing: When a stock gets listed on two or more stock exchanges, we say that the stock has a d...
Read ArticleThe company has capitalised on recent share price appreciation driven by emerging data from broad-ba...
Read ArticleThe cancer therapeutics developer expects its shares will swap hands again by Monday.
Read ArticleStockhead’s resident Health and Biotech expert Tim Boreham is putting down the stethoscope and picki...
Read ArticleKazia has presented at the annual Congress of the European Society for Medical Oncology (ESMO), held...
Read ArticleResults from phase II study of its brain cancer therapeutic GDC-0084 are expected next quarter.
Read ArticleThe company is in discussion with clinicians and potential collaborators regarding the strategy for...
Read ArticleSydney-based oncology biotechnology company Kazia Therapeutics, formerly known as Novogen, h...
Read ArticleThe awards are run by the Australian New Zealand Leadership Forum which brings senior businesses and...
Read ArticleToxicity can be a significant challenge in the treatment of childhood cancer, so it is very encourag...
Read ArticleThe report points out Kazia’s accelerated 2023 GDC-0084 approval and maintains its base case 2024 la...
Read ArticleThe four award winners will be announced at a dinner in Auckland, New Zealand, next Thursday, Septem...
Read ArticleIf GDC-0084 is successful in phase-III, the drug will launch into a disease area that has been poorl...
Read ArticleSelection of an INN is usually a necessary step before a new drug can be submitted for commercial re...
Read ArticleAustralia has a well-regulated and high-quality health sector, while its medical research and health...
Read ArticleAbout 240,000 women are diagnosed with ovarian cancer each year worldwide and it is the eighth most...
Read ArticleAustralian oncology-focused biotechnology company Kazia Therapeutics (ASX:KZA) says it has c...
Read ArticleCompanies and institutions that provide medical assistance and services, manufactures of medical equ...
Read ArticleMemorial Sloan Kettering Cancer Center in New York will investigate the potential use of Kazia’s inv...
Read ArticleBiotechnology company Kazia Therapeutics (ASX: KZA) has taken a definitive step towards proving the...
Read ArticleEdison Investment Research has assigned an indicative valuation range of $84–135 million or $1.35–2....
Read ArticleSydney-based Hishenk Pty Ltd now holds 10.835 million shares after placement and on-market purchases...
Read ArticleA new collaboration with the Alliance for clinical trials in oncology means Kazia will soon have fou...
Read ArticleThe healthcare industry of Australia plays a major role in developing the country’s economy. The hea...
Read Article
Open an account with an online broker of your choice. If you do not have an existing broker, consider Vested Equities' A$9.50 flat fee platform.
Sign up now »Place your order however you wish. If you need advice on buying or selling, you should seek the assistance of a full service financial adviser experienced in small cap equities.
